Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats

Neuroscience

Volumn 284, Issue , 2015, Pages 775-797

  Glover, M E ^a   Pugh, P C ^a   Jackson, N L ^a   Cohen, J L ^a   Fant, A D ^b   Akil, H ^c   Clinton, S M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Amygdala; Antidepressant; Anxiety; Depression; Hippocampus; Neurodevelopment

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BRAIN DEVELOPMENT; BRAIN TISSUE; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; EMOTION; ENERGY METABOLISM; FEMALE; FORCED SWIM TEST; GENE EXPRESSION; HIPPOCAMPUS; MALE; MATERNAL BEHAVIOR; MICROARRAY ANALYSIS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PERINATAL DRUG EXPOSURE; PREGNANCY OUTCOME; PROGENY; RAT; SYNAPSE VESICLE; AMYGDALA; ANIMAL; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GROWTH, DEVELOPMENT AND AGING; NEWBORN; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; SPRAGUE DAWLEY RAT;

AMYGDALA; ANIMALS; ANIMALS, NEWBORN; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC PREDISPOSITION TO DISEASE; HIPPOCAMPUS; MALE; MATERNAL BEHAVIOR; PAROXETINE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS;

EID: 84911429527     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.10.044     Document Type: Article

References (161)

1. Alwan S., Friedman J.M. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009, 23:493-509.
2. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., Friedman J.M. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007, 356:2684-2692.
3. Alwan S., Reefhuis J., Rasmussen S.A., Friedman J.M. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011, 51:264-270.
4. Andersen S.L., Greene-Colozzi E.A., Sonntag K.C. A novel, multiple symptom model of obsessive-compulsive-like behaviors in animals. Biol Psychiatry 2010, 68:741-747.
5. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004, 306:879-881.
6. Ansorge M., Morelli E., Gingrich J. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 2008, 28:199-207.
7. Bairy K.L., Madhyastha S., Ashok K.P., Bairy I., Malini S. Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2007, 79:1-11.
8. Bakker M.K., Kerstjens-Frederikse W.S., Buys C.H., de Walle H.E., de Jong-van den Berg L.T. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010, 88:94-100.
9. Ballaz S.J., Akil H., Watson S.J. The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience 2007, 149:192-202.
10. Ballaz S.J., Akil H., Watson S.J. Analysis of 5-HT6 and 5-HT7 receptor gene expression in rats showing differences in novelty-seeking behavior. Neuroscience 2007, 147:428-438.
11. Bar-Oz B., Einarson T., Einarson A., Boskovic R., O'Brien L., Malm H., Berard A., Koren G. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007, 29:918-926.
12. Bennett H.A., Einarson A., Taddio A., Koren G., Einarson T.R. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004, 103:698-709.
13. Berard A., Ramos E., Rey E., Blais L., St-Andre M., Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007, 80:18-27.
14. Blanchard M.M., Mendelsohn D., Stamp J.A. The HR/LR model: further evidence as an animal model of sensation seeking. Neurosci Biobehav Rev 2009, 33:1145-1154.
15. Borri C., Mauri M., Oppo A., Banti S., Rambelli C., Ramacciotti D., Montagnani M.S., Camilleri V., Cortopassi S., Bettini A., Ricciardulli S., Rucci P., Montaresi S., Cassano G.B. Axis I psychopathology and functional impairment at the third month of pregnancy: results from the Perinatal Depression-Research and Screening Unit (PND-ReScU) study. J Clin Psychiatry 2008, 69:1617-1624.
16. Bosch O.J. Maternal nurturing is dependent on her innate anxiety: the behavioral roles of brain oxytocin and vasopressin. Horm Behav 2011, 59:202-212.
17. Bourke C.H., Capello C.F., Rogers S.M., Yu M.L., Boss-Williams K.A., Weiss J.M., Stowe Z.N., Owens M.J. Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment. Psychopharmacology (Berl) 2013, 228:231-241.
18. Bourke C.H., Stowe Z.N., Neigh G.N., Olson D.E., Owens M.J. Prenatal exposure to escitalopram and/or stress in rats produces limited effects on endocrine, behavioral, or gene expression measures in adult male rats. Neurotoxicol Teratol 2013, 39:100-109.
19. Caccia S., Cappi M., Fracasso C., Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) 1990, 100:509-514.
20. Caldji C., Diorio J., Meaney M.J. Variations in maternal care in infancy regulate the development of stress reactivity. Biol Psychiatry 2000, 48:1164-1174.
21. Calvo N., Cecchi M., Kabbaj M., Watson S.J., Akil H. Differential effects of social defeat in rats with high and low locomotor response to novelty. Neuroscience 2011, 183:81-89.
22. Capriles N., Watson S., Akil H. Individual differences in the improvement of cocaine-induced place preference response by the 5-HT2C receptor antagonist SB242084 in rats. Psychopharmacology (Berl) 2012, 220:731-740.
23. Carlson J.N., Visker K.E., Nielsen D.M., Keller R.W., Glick S.D. Chronic antidepressant drug treatment reduces turning behavior and increases dopamine levels in the medial prefrontal cortex. Brain Res 1996, 707:122-126.
24. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., Gilles A., Gaylor E., DeBattista A., Hoyme H.E. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003, 142:402-408.
25. Chen F., Wegener G., Madsen T.M., Nyengaard J.R. Mitochondrial plasticity of the hippocampus in a genetic rat model of depression after antidepressant treatment. Synapse 2013, 67:127-134.
26. Clements C.C., Castro V.M., Blumenthal S.R., Rosenfield H.R., Murphy S.N., Fava M., Erb J.L., Churchill S.E., Kaimal A.J., Doyle A.E., Robinson E.B., Smoller J.W., Kohane I.S., Perlis R.H. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry 2014, 10.1038/mp.2014.90.
27. Clinton S.M., Miller S., Watson S.J., Akil H. Prenatal stress does not alter innate novelty-seeking behavioral traits, but differentially affects individual differences in neuroendocrine stress responsivity. Psychoneuroendocrinology 2008, 33:162-177.
28. Clinton S.M., Bedrosian T.A., Abraham A.D., Watson S.J., Akil H. Neural and environmental factors impacting maternal behavior differences in high- versus low-novelty-seeking rats. Horm Behav 2010, 57:463-473.
29. Clinton S.M., Kerman I.A., Orr H.R., Bedrosian T.A., Abraham A.D., Simpson D.N., Watson S.J., Akil H. Pattern of forebrain activation in high novelty-seeking rats following aggressive encounter. Brain Res 2011, 1422:20-31.
30. Clinton S.M., Stead J.D., Miller S., Watson S.J., Akil H. Developmental underpinnings of differences in rodent novelty-seeking and emotional reactivity. Eur J Neurosci 2011, 34:994-1005.
31. Clinton S.M., Watson S.J., Akil H. High novelty-seeking rats are resilient to negative physiological effects of the early life stress. Stress 2014, 17:97-107.
32. Cole J.A., Ephross S.A., Cosmatos I.S., Walker A.M. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16:1075-1085.
33. Cordes S.P. Molecular genetics of the early development of hindbrain serotonergic neurons. Clin Genet 2005, 68:487-494.
34. Croen L.A., Grether J.K., Yoshida C.K., Odouli R., Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011, 68:1104-1112.
35. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005, 29:547-569.
36. Cummings J.A., Clinton S.M., Perry A.N., Akil H., Becker J.B. Male rats that differ in novelty exploration demonstrate distinct patterns of sexual behavior. Behav Neurosci 2013, 127:47-58.
37. Darling R.D., Alzghoul L., Zhang J., Khatri N., Paul I.A., Simpson K.L., Lin R.C. Perinatal citalopram exposure selectively increases locus ceruleus circuit function in male rats. J Neurosci 2011, 31:16709-16715.
38. Dayan J., Creveuil C., Herlicoviez M., Herbel C., Baranger E., Savoye C., Thouin A. Role of anxiety and depression in the onset of spontaneous preterm labor. Am J Epidemiol 2002, 155:293-301.
39. DeVane C.L. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 1999, 19:443-466.
40. Diav-Citrin O., Shechtman S., Weinbaum D., Wajnberg R., Avgil M., Di Gianantonio E., Clementi M., Weber-Schoendorfer C., Schaefer C., Ornoy A. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008, 66:695-705.
41. Dinopoulos A., Dori I., Parnavelas J.G. The serotonin innervation of the basal forebrain shows a transient phase during development. Brain Res Dev Brain Res 1997, 99:38-52.
42. Donovan S.L., Mamounas L.A., Andrews A.M., Blue M.E., McCasland J.S. GAP-43 is critical for normal development of the serotonergic innervation in forebrain. J Neurosci 2002, 22:3543-3552.
43. Eilam D., Golani I. The ontogeny of exploratory behavior in the house rat (Rattus rattus): the mobility gradient. Develop Psychobiol 1988, 21:679-710.
44. Einarson A., Pistelli A., DeSantis M., Malm H., Paulus W.D., Panchaud A., Kennedy D., Einarson T.R., Koren G. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008, 165:749-752.
45. Everett J.W., Sawyer C.H. A neural timing factor in the mechanism by which progesterone advances ovulation in the cyclic rat. Endocrinology 1949, 45:581-595. illust.
46. Feenstra M.G., van Galen H., Te Riele P.J., Botterblom M.H., Mirmiran M. Decreased hypothalamic serotonin levels in adult rats treated neonatally with clomipramine. Pharmacol Biochem Behav 1996, 55:647-652.
47. Flagel S.B., Waselus M., Clinton S.M., Watson S.J., Akil H. Antecedents and consequences of drug abuse in rats selectively bred for high and low response to novelty. Neuropharmacology 2014, 76(Pt B):425-436.
48. Forcelli P.A., Heinrichs S.C. Teratogenic effects of maternal antidepressant exposure on neural substrates of drug-seeking behavior in offspring. Addict Biol 2008, 13:52-62.
49. Francis D.D., Champagne F.A., Liu D., Meaney M.J. Maternal care, gene expression, and the development of individual differences in stress reactivity. Ann N Y Acad Sci 1999, 896:66-84.
50. Frankova S., Mikulecka A. Ontogeny of social behavior of pups of laboratory rats genetically selected for activity level. Act Nerv Super (Praha) 1990, 32:167-173.
51. Garcia-Fuster M.J., Parks G.S., Clinton S.M., Watson S.J., Akil H., Civelli O. The melanin-concentrating hormone (MCH) system in an animal model of depression-like behavior. Eur Neuropsychopharmacol 2012, 22(8):607-613.
52. Gaspar P., Cases O., Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003, 4:1002-1012.
53. Gentile S., Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011, 128:1-9.
54. Goodnick P.J. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacol Bull 1991, 27:503-512.
55. Grigoriadis S., VonderPorten E.H., Mamisashvili L., Roerecke M., Rehm J., Dennis C.L., Koren G., Steiner M., Mousmanis P., Cheung A., Ross L.E. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013, 74:e293-e308.
56. Hansen H.H., Sanchez C., Meier E. Neonatal administration of the selective serotonin reuptake inhibitor Lu 10-134-C increases forced swimming-induced immobility in adult rats: a putative animal model of depression?. J Pharmacol Exp Ther 1997, 283:1333-1341.
57. Harrington R.A., Lee L.C., Crum R.M., Zimmerman A.W., Hertz-Picciotto I. Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res 2013, 6:149-168.
58. Harris S.S., Maciag D., Simpson K.L., Lin R.C., Paul I.A. Dose-dependent effects of neonatal SSRI exposure on adult behavior in the rat. Brain Res 2012, 1429:52-60.
59. Hartley P.S., John Sheward W., French K., Horn J.M., Holmes M.C., Harmar A.J. Food-entrained rhythmic expression of PER2 and BMAL1 in murine megakaryocytes does not correlate with circadian rhythms in megakaryopoiesis. J Thromb Haemost 2008, 6:1144-1152.
60. Hayes R.M., Wu P., Shelton R.C., Cooper W.O., Dupont W.D., Mitchel E., Hartert T.V. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol 2012, 207(49):e41-e49.
61. Heim C.P.P.M., Nemeroff C.B. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology 2004, 29:641-648.
62. Hendrick V., Stowe Z.N., Altshuler L.L., Hwang S., Lee E., Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003, 160:993-996.
63. Hilakivi L.A., Hilakivi I. Increased adult behavioral 'despair' in rats neonatally exposed to desipramine or zimeldine: an animal model of depression?. Pharmacol Biochem Behav 1987, 28:367-369.
64. Hilakivi L.A., Hilakivi I., Ahtee L., Haikala H., Attila M. Effect of neonatal nomifensine exposure on adult behavior and brain monoamines in rats. J Neural Transm 1987, 70:99-116.
65. Hilakivi L.A., Hilakivi I., Kiianmaa K. Neonatal antidepressant administration suppresses concurrent active (REM) sleep and increases adult alcohol consumption in rats. Alcohol Alcohol Suppl 1987, 1:339-343.
66. Hilakivi L.A., Taira T., Hilakivi I., Loikas P. Neonatal treatment with monoamine uptake inhibitors alters later response in behavioural 'despair' test to beta and GABA-B receptor agonists. Pharmacol Toxicol 1988, 63:57-61.
67. Homberg J.R., Schubert D., Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 2010, 31:60-65.
68. Hroudova J., Fisar Z. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinol Lett 2010, 31:336-342.
69. Hu Y., Zhou J., Fang L., Liu H., Zhan Q., Luo D., Zhou C., Chen J., Li Q., Xie P. Hippocampal synaptic dysregulation of exo/endocytosis-associated proteins induced in a chronic mild-stressed rat model. Neuroscience 2013, 230:1-12.
70. Hyttel J. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry 1993, 47(suppl. 30):5-12.
71. Insausti R., Cebada-Sanchez S., Marcos P. Postnatal development of the human hippocampal formation. Adv Anat Embryol Cell Biol 2010, 206:1-86.
72. Jama A., Cecchi M., Calvo N., Watson S.J., Akil H. Inter-individual differences in novelty-seeking behavior in rats predict differential responses to desipramine in the forced swim test. Psychopharmacology 2008, 198(3):333-340.
73. Jimenez-Solem E., Andersen J.T., Petersen M., Broedbaek K., Jensen J.K., Afzal S., Gislason G.H., Torp-Pedersen C., Poulsen H.E. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012, 2.
74. Jimenez-Solem E., Andersen J.T., Petersen M., Broedbaek K., Andersen N.L., Torp-Pedersen C., Poulsen H.E. Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS One 2013, 8:e63034.
75. Kabbaj M. Neurobiological bases of individual differences in emotional and stress responsiveness: high responders-low responders model. Arch Neurol 2004, 61:1009-1012.
76. Kabbaj M., Devine D.P., Savage V.R., Akil H. Neurobiological correlates of individual differences in novelty-seeking behavior in the rat: differential expression of stress-related molecules. J Neurosci 2000, 20:6983-6988.
77. Kallen B., Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006, 21:221-222.
78. Karanges E., Li K.M., Motbey C., Callaghan P.D., Katsifis A., McGregor I.S. Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents?. Int J Neuropsychopharmacol 2011, 14:491-504.
79. Karanges E.A., Kashem M.A., Sarker R., Ahmed E.U., Ahmed S., Van Nieuwenhuijzen P.S., Kemp A.H., McGregor I.S. Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of "paradoxical" antidepressant responses in young persons. Front Pharmacol 2013, 4:86.
80. Kerman I.A., Clinton S.M., Bedrosian T.A., Abraham A.D., Rosenthal D.T., Akil H., Watson S.J. High novelty-seeking predicts aggression and gene expression differences within defined serotonergic cell groups. Brain Res 2011, 1419:34-45.
81. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
82. Kessler R.C.B.P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005, 62:593-602.
83. Kinney G.G., Vogel G.W., Feng P. Decreased dorsal raphe nucleus neuronal activity in adult chloral hydrate anesthetized rats following neonatal clomipramine treatment: implications for endogenous depression. Brain Res 1997, 756:68-75.
84. Klinger G., Frankenthal D., Merlob P., Diamond G., Sirota L., Levinson-Castiel R., Linder N., Stahl B., Inbar D. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol 2011, 31:615-620.
85. Kornum J.B., Nielsen R.B., Pedersen L., Mortensen P.B., Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010, 2:29-36.
86. Ladd C.O.H.R.L., Thrivikraman K.V., Nemeroff C.B., Meaney M.J., Plotsky P.M. Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res 2000, 122:81-103.
87. Landgraf R., Wigger A. High versus low anxiety-related behavior rats: an animal model of extremes in trait anxiety. Behav Genet 2002, 32:301-314.
88. Lee L.J. Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotox Res 2009, 15:212-223.
89. Lee L.J., Lee L.J. Neonatal fluoxetine exposure alters motor performances of adolescent rats. Dev Neurobiol 2012, 72:1122-1132.
90. Lesch K.P., Waider J. Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuron 2012, 76:175-191.
91. Li Y., Couch L., Higuchi M., Fang J.L., Guo L. Mitochondrial dysfunction induced by sertraline, an antidepressant agent. Toxicol Sci 2012, 127:582-591.
92. Lisboa S., Oliveira P., Costa L., Venâncio E., Moreira E. Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007, 80:49-56.
93. Louik C., Lin A.E., Werler M.M., Hernandez-Diaz S., Mitchell A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007, 356:2675-2683.
94. Lowry C.A., Hale M.W., Evans A.K., Heerkens J., Staub D.R., Gasser P.J., Shekhar A. Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann N Y Acad Sci 2008, 1148:86-94.
95. Maciag D., Simpson K., Coppinger D., Lu Y., Wang Y., Lin R., Paul I. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006, 31:47-57.
96. Maciag D., Williams L., Coppinger D., Paul I. Neonatal citalopram exposure produces lasting changes in behavior which are reversed by adult imipramine treatment. Eur J Pharmacol 2006, 532:265-269.
97. Malberg J.E., Duman R.S. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 2003, 28:1562-1571.
98. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000, 20:9104-9110.
99. Malm H., Klaukka T., Neuvonen P.J. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005, 106:1289-1296.
100. Marcus S.M. Depression during pregnancy: rates, risks and consequences - Motherisk Update 2008. Can J Clin Pharmacol 2009, 16:e15-e22.
101. Marcussen A.B., Flagstad P., Kristjansen P.E., Johansen F.F., Englund U. Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats. Acta Neurol Scand 2008, 117:94-100.
102. Marquez C., Nadal R., Armario A. Influence of reactivity to novelty and anxiety on hypothalamic-pituitary-adrenal and prolactin responses to two different novel environments in adult male rats. Behav Brain Res 2006, 168:13-22.
103. McAllister B.B., Kiryanova V., Dyck R.H. Behavioural outcomes of perinatal maternal fluoxetine treatment. Neuroscience 2012, 226:356-366.
104. Meaney M.J. Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu Rev Neurosci 2001, 24:1161-1192.
105. Milne R.J., Goa K.L. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991, 41:450-477.
106. Mirmiran M., van de Poll N.E., Corner M.A., van Oyen H.G., Bour H.L. Suppression of active sleep by chronic treatment with chlorimipramine during early postnatal development: effects upon adult sleep and behavior in the rat. Brain Res 1981, 204:129-146.
107. Muigg P., Hoelzl U., Palfrader K., Neumann I., Wigger A., Landgraf R., Singewald N. Altered brain activation pattern associated with drug-induced attenuation of enhanced depression-like behavior in rats bred for high anxiety. Biol Psychiatry 2007, 61:782-796.
108. Musazzi L., Mallei A., Tardito D., Gruber S.H., El Khoury A., Racagni G., Mathe A.A., Popoli M. Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression. J Psychiatr Res 2010, 44:511-520.
109. Noorlander C., Ververs F., Nikkels P., van Echteld C., Visser G., Smidt M. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS one 2008, 3.
110. Oberlander T.F. Fetal serotonin signaling: setting pathways for early childhood development and behavior. J Adolesc Health 2012, 55:S9-S16.
111. Oberlander T.F., Grunau R.E., Fitzgerald C., Papsdorf M., Rurak D., Riggs W. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005, 115:411-425.
112. Oberlander T.F., Bonaguro R.J., Misri S., Papsdorf M., Ross C.J., Simpson E.M. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008, 13:65-73.
113. Oberlander T.F., Grunau R., Mayes L., Riggs W., Rurak D., Papsdorf M., Misri S., Weinberg J. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 2008, 84:689-697.
114. Oberlander T.F., Warburton W., Misri S., Riggs W., Aghajanian J., Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008, 83:68-76.
115. Oberlander T., Gingrich J., Ansorge M. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 2009, 86:672-677.
116. Oberlander T.F., Papsdorf M., Brain U.M., Misri S., Ross C., Grunau R.E. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3years of age. Arch Pediatr Adolesc Med 2010, 164:444-451.
117. Olivier J.D., Blom T., Arentsen T., Homberg J.R. The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1400-1408.
118. Overstreet D.H. Selective breeding for increased cholinergic function: development of a new animal model of depression. Biol Psychiatry 1986, 21:49-58.
119. Overstreet D.H., Booth R.A., Dana R., Risch S.C., Janowsky D.S. Enhanced elevation of corticosterone following arecoline administration to rats selectively bred for increased cholinergic function. Psychopharmacology (Berl) 1986, 88:129-130.
120. Overstreet D.H., Janowsky D.S., Gillin J.C., Shiromani P.J., Sutin E.L. Stress-induced immobility in rats with cholinergic supersensitivity. Biol Psychiatry 1986, 21:657-664.
121. Pawluski J.L., Charlier T.D., Fillet M., Houbart V., Crispin H.T., Steinbusch H.W., van den Hove D.L. Chronic fluoxetine treatment and maternal adversity differentially alter neurobehavioral outcomes in the rat dam. Behav Brain Res 2012, 228:159-168.
122. Pedersen L.H., Henriksen T.B., Vestergaard M., Olsen J., Bech B.H. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009, 339:b3569.
123. Peng Z.W., Xue F., Wang H.N., Zhang R.G., Chen Y.C., Wang Y., Zhang L.Y., Fan J., Tan Q.R. Paroxetine up-regulates neurogenesis in hippocampus-derived neural stem cell from fetal rats. Mol Cell Biochem 2013, 375:105-113.
124. Piazza P.V., Deminiere J.M., Le Moal M., Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science 1989, 245:1511-1513.
125. Piazza P.V., Deroche V., Deminiere J.M., Maccari S., Le Moal M., Simon H. Corticosterone in the range of stress-induced levels possesses reinforcing properties: implications for sensation-seeking behaviors. Proc Natl Acad Sci USA 1993, 90:11738-11742.
126. Popa D., Lena C., Alexandre C., Adrien J. Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J Neurosci 2008, 28:3546-3554.
127. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
128. Preskorn S.H. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993, 54(suppl.):14-34. [discussion 55-16].
129. Rai D., Lee B.K., Dalman C., Golding J., Lewis G., Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. Br Med J 2013, 346.
130. Ross L.E., Grigoriadis S., Mamisashvili L., Vonderporten E.H., Roerecke M., Rehm J., Dennis C.L., Koren G., Steiner M., Mousmanis P., Cheung A. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013, 70:436-443.
131. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
132. Sapolsky R.M., Meaney M.J. Maturation of the adrenocortical stress response: neuroendocrine control mechanisms and the stress hyporesponsive period. Brain Res 1986, 396:64-76.
133. Sarkar A., Chachra P., Kennedy P., Pena C.J., Desouza L.A., Nestler E.J., Vaidya V.A. Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior. Neuropsychopharmacology 2014, 39(9):2221-2232.
134. Sillaber I., Panhuysen M., Henniger M.S., Ohl F., Kuhne C., Putz B., Pohl T., Deussing J.M., Paez-Pereda M., Holsboer F. Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 2008, 200:557-572.
135. Simmons R.K., Stringfellow S.A., Glover M.E., Wagle A.A., Clinton S.M. DNA methylation markers in the postnatal developing rat brain. Brain Res 2013, 1533:26-36.
136. Simpson K.L., Weaver K.J., de Villers-Sidani E., Lu J.Y., Cai Z., Pang Y., Rodriguez-Porcel F., Paul I.A., Merzenich M., Lin R.C. Perinatal antidepressant exposure alters cortical network function in rodents. Proc Natl Acad Sci USA 2011, 108:18465-18470.
137. Stead J.D., Clinton S., Neal C., Schneider J., Jama A., Miller S., Vazquez D.M., Watson S.J., Akil H. Selective breeding for divergence in novelty-seeking traits: heritability and enrichment in spontaneous anxiety-related behaviors. Behav Genet 2006, 36:697-712.
138. Stead J.D., Neal C., Meng F., Wang Y., Evans S., Vazquez D.M., Watson S.J., Akil H. Transcriptional profiling of the developing rat brain reveals that the most dramatic regional differentiation in gene expression occurs postpartum. J Neurosci 2006, 26:345-353.
139. Stedenfeld K.A., Clinton S.M., Kerman I.A., Akil H., Watson S.J., Sved A.F. Novelty-seeking behavior predicts vulnerability in a rodent model of depression. Physiol Behav 2011, 103:210-216.
140. Thompson M.R., Li K.M., Clemens K.J., Gurtman C.G., Hunt G.E., Cornish J.L., McGregor I.S. Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. Neuropsychopharmacology 2004, 29:694-704.
141. Van den Hove D.L., Blanco C.E., Scheepens A., Desbonnet L., Myint A.M., Leonard B.E., Prickaerts J., Steinbusch H.W. Prenatal maternal paroxetine treatment and neonatal mortality in the rat: a preliminary study. Neonatology 2008, 93:52-55.
142. Vasilakis-Scaramozza C., Aschengrau A., Cabral H., Jick S.S. Antidepressant use during early pregnancy and the risk of congenital anomalies. Pharmacotherapy 2013, 33:693-700.
143. Vazquez-Palacios G., Bonilla-Jaime H., Velazquez-Moctezuma J. Antidepressant effects of nicotine and fluoxetine in an animal model of depression induced by neonatal treatment with clomipramine. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:39-46.
144. Veenema A.H., Torner L., Blume A., Beiderbeck D.I., Neumann I.D. Low inborn anxiety correlates with high intermale aggression: link to ACTH response and neuronal activation of the hypothalamic paraventricular nucleus. Horm Behav 2007, 51:11-19.
145. Velazquez-Moctezuma J., Diaz Ruiz O. Neonatal treatment with clomipramine increased immobility in the forced swim test: an attribute of animal models of depression. Pharmacol Biochem Behav 1992, 42:737-739.
146. Verheij M.M., Veenvliet J.V., Groot Kormelink T., Steenhof M., Cools A.R. Individual differences in the sensitivity to serotonergic drugs: a pharmacobehavioural approach using rats selected on the basis of their response to novelty. Psychopharmacology (Berl) 2009, 205:441-455.
147. Vijayakumar M., Meti B.L. Alterations in the levels of monoamines in discrete brain regions of clomipramine-induced animal model of endogenous depression. Neurochem Res 1999, 24:345-349.
148. Vogel G., Neill D., Hagler M., Kors D. A new animal model of endogenous depression: a summary of present findings. Neurosci Biobehav Rev 1990, 14:85-91.
149. Vorhees C.V., Acuff-Smith K.D., Schilling M.A., Fisher J.E., Moran M.S., Buelke-Sam J. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994, 23:194-205.
150. Weaver K.J., Paul I.A., Lin R.C., Simpson K.L. Neonatal exposure to citalopram selectively alters the expression of the serotonin transporter in the hippocampus: dose-dependent effects. Anat Rec (Hoboken) 2010, 293:1920-1932.
151. White D.A., Kalinichev M., Holtzman S.G. Locomotor response to novelty as a predictor of reactivity to aversive stimuli in the rat. Brain Res 2007, 1149:141-148.
152. Wichman C.L., Moore K.M., Lang T.R., St Sauver J.L., Heise R.H., Watson W.J. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009, 84:23-27.
153. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.
154. Wogelius P., Norgaard M., Gislum M., Pedersen L., Munk E., Mortensen P.B., Lipworth L., Sorensen H.T. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006, 17:701-704.
155. Yang D., Li Q., Fang L., Cheng K., Zhang R., Zheng P., Zhan Q., Qi Z., Zhong S., Xie P. Reduced neurogenesis and pre-synaptic dysfunction in the olfactory bulb of a rat model of depression. Neuroscience 2011, 192:609-618.
156. Yannielli P.C., Kargieman L., Gregoretti L., Cardinali D.P. Effects of neonatal clomipramine treatment on locomotor activity, anxiety-related behavior and serotonin turnover in Syrian hamsters. Neuropsychobiology 1999, 39:200-206.
157. Ying S.Y., Gove S., Fang V.S., Greep R.O. Ovulation in postpartum rats. Endocrinology 1973, 92:108-116.
158. Yonkers K.A., Wisner K.L., Stewart D.E., Oberlander T.F., Dell D.L., Stotland N., Ramin S., Chaudron L., Lockwood C. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009, 114:703-713.
159. Yoo H.S., Bunnell B.N., Crabbe J.B., Kalish L.R., Dishman R.K. Failure of neonatal clomipramine treatment to alter forced swim immobility: chronic treadmill or activity-wheel running and imipramine. Physiol Behav 2000, 70:407-411.
160. Zeskind P.S., Stephens L.E. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004, 113:368-375.
161. Zhang J., Darling R.D., Paul I.A., Simpson K.L., Chen K., Shih J.C., Lin R.C. Altered expression of tyrosine hydroxylase in the locus coeruleus noradrenergic system in citalopram neonatally exposed rats and monoamine oxidase a knockout mice. Anat Rec (Hoboken) 2011, 294:1685-1697.